Clinical Trial Update: A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia [Phase 2]

View source ↗

Summary

Phase II open-label trial evaluating subcutaneous canakinumab (anti-IL-1β) for patients with low- to intermediate-1-risk myelodysplastic syndromes and chronic m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: RECRUITING